Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011

American Journal of Hematology

Volumn 90, Issue 9, 2015, Pages 790-795

  Al Hamadani, Mohammed ^a   Habermann, Thomas M ^b   Cerhan, James R ^b   Macon, William R ^b   Maurer, Matthew J ^b   Go, Ronald S ^b  

^a GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BURKITT LYMPHOMA; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; FOLLICULAR LYMPHOMA; HAIRY CELL LEUKEMIA; HIGH RISK POPULATION; HUMAN; LONGITUDINAL STUDY; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; UNITED STATES; B LYMPHOCYTE; FACTUAL DATABASE; LEUKEMIA, HAIRY CELL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE-CELL, ANAPLASTIC; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; MORTALITY; NOMENCLATURE; PATHOLOGY; SURVIVAL; T LYMPHOCYTE;

ADULT; AGED; B-LYMPHOCYTES; BURKITT LYMPHOMA; DATABASES, FACTUAL; FEMALE; HUMANS; LEUKEMIA, HAIRY CELL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LONGITUDINAL STUDIES; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE-CELL, ANAPLASTIC; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TERMINOLOGY AS TOPIC; UNITED STATES;

EID: 84939573803     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24086     Document Type: Article

References (34)

1. Harris NL, Jaffe, ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
2. Percy C, Vanholten, V, Muir G, et al. New international classification of diseases for oncology (Icd-O, 2nd Edition) and the neoplasm chapter of the 10th revision of the international classification of diseases (Icd-10). Lab Invest 1990;62:A113-A113.
3. Percy C FA, Ries L. Conversion of neoplasms by topography and morphology from the International Classification of Diseases for Oncology, 2nd ed. International Classification of Diseases for Oncology, 3rd ed. Bethesda: Cancer Statistics Branch, DCCPS, SEER Program, NationalCancer Institute; 2001.
4. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-3918.
5. Fritz AG, Percy C, Jack A, et al. International classification of diseases for oncology: ICD-O. Geneva, Switzerland: World Health Organization; 2000. vii, pp 240.
6. Jaffe ES HN, Stein H, Vardiman JW, editors. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
7. Vardiman JW, Thiele, J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114:937-951.
8. Morton LM, Wang, SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265-276.
9. Morton LM, Turner, JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007;110:695-708.
10. National Cancer Data Base. https://www.facs.org/quality%20programs/cancer/ncdb. Accessed September 2, 2014.
11. Glass AG, Karnell LH, Menck HR. The National Cancer Data Base report on non-Hodgkin's lymphoma. Cancer 1997;80:2311-2320.
12. Phillips JL, Stewart AK, editors. Facility Oncology Registry Data Standards (FORDS): Revised for 2013. Chicago, IL: American College of Surgeons; 2013.
13. North American Association of Center Cancer Registries. http://www.naaccr.org/. Accessed October 16, 2014.
14. United States Census Bureau. Geographic Terms and Concepts - Census Divisions and Census Regions of the United States. United States Census Bureau. http://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf. Accessed February 2, 2015.
15. Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: Analysis of the Surveillance, Epidemiology, and End Results database. Cancer 2013;119:629-638.
16. Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 2009;33:197-207.
17. Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008;19:379-390.
18. Evens AM, Antillon, M, Aschebrook-Kilfoy B, et al. Racial disparities in Hodgkin's lymphoma: A comprehensive population-based analysis. Ann Oncol 2012;23:2128-2137.
19. Laurini JA, Perry, AM, Boilesen E, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood 2012;120:4795-4801.
20. Makharia GK, Mulder, CJ, Goh KL, et al. Issues associated with the emergence of coeliac disease in the Asia-Pacific region: A working party report of the World Gastroenterology Organization and the Asian Pacific Association of Gastroenterology. J Gastroenterol Hepatol 2014;29:666-677.
21. Tan SY, Chuang, SS, Tang T, et al. Type II EATL (epitheliotropic intestinal T-cell lymphoma): A neoplasm of intra-epithelial T-cells with predominant CD8alphaalpha phenotype. Leukemia 2013;27:1688-1696.
22. Goebel T, Waters MR, O'Rourke DH. The late Pleistocene dispersal of modern humans in the Americas. Science 2008;319:1497-1502.
23. Yang QP, Zhang, WY, Yu JB, et al. Subtype distribution of lymphomas in Southwest China: Analysis of 6, 382 cases using WHO classification in a single institution. Diagn Pathol 2011;6:77.
24. Falchook GS, Vega, F, Dang NH, et al. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 2009;20:1080-1085.
25. Kotlyar DS, Osterman, MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:36-41.e1.
26. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-1517.
27. Naresh KN, Srinivas V, Soman CS. Distribution of various subtypes of non-Hodgkin's lymphoma in India: A study of 2773 lymphomas using R.E.A.L. and WHO Classifications. Ann Oncol 2000;11:63-67.
28. Sant M, Allemani, C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010;116:3724-3734.
29. Yoon SO, Suh, C, Lee DH, et al. Distribution of lymphoid neoplasms in the Republic of Korea: Analysis of 5318 cases according to the World Health Organization classification. Am J Hematol 2010;85:760-764.
30. van Leeuwen MT, Turner, JJ, Joske DJ, et al. Lymphoid neoplasm incidence by WHO subtype in Australia 1982-2006. Int J Cancer 2014;135:2146-2156.
31. SEER Cancer Statistics Review 1975-2011. Surveillance Epidemiology, and End Results Program. http://seer.cancer.gov/csr/1975_2011/sections.html. Accessed March 14, 2015.
32. Drug and Biologic Approval and IND Activity Reports. US Food and Drug Administration. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/default.htm. Accessed November 3, 2014.
33. Piro LD, Carrera, CJ, Carson DA, et al. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990;322:1117-1121.
34. Bilimoria KY, Bentrem, DJ, Stewart AK, et al. Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: Implications for studies that use the National Cancer Data Base. J Clin Oncol 2009;27:4177-4181.